Evidence map›Paper›PMID 37272563›Full record

ArticleJournal of Korean medical science2023

Within-Host Evolution of SARS-CoV-2 in a B-Cell Depleted Patient With Successful Treatment.

Yae Jee Baek, Gemma Park, Jun Yong Choi, Eun Jin Kim, Bryan Inho Kim, Jin Gwack, Ji Ye Jung

Open access · goldAbstract readCase Reports
In one paragraph

Article in Journal of Korean medical science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Yae Jee Baek *Division of Infectious Diseases, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0003-0994-4940
Gemma Park *Korea Disease Control and Prevention Agency, Osong, Korea.ORCID https://orcid.org/0000-0002-0561-5288
Jun Yong ChoiDivision of Infectious Diseases, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-2775-3315
Eun Jin KimKorea Disease Control and Prevention Agency, Osong, Korea.ORCID https://orcid.org/0000-0001-6784-8004
Bryan Inho KimKorea Disease Control and Prevention Agency, Osong, Korea.ORCID https://orcid.org/0000-0002-1798-5315
Jin GwackKorea Disease Control and Prevention Agency, Osong, Korea. gwackjin@korea.kr.ORCID https://orcid.org/0000-0003-0932-9542
Ji Ye JungDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. stopyes@yuhs.ac.ORCID https://orcid.org/0000-0003-1589-4142
Korea Disease Control and Prevention Agency · KRYonsei University · KRSoonchunhyang University Hospital Seoul · KR

Funding

National Research Foundation of Korea NRF-2018R1A5A2025079
6 · The paper itself

Abstract

Prolonged viral shedding of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an immunocompromised host is a challenge as the treatment and infection control for chronic coronavirus disease 2019 infection is not well established and there is a potential risk of new variants emerging. A 48-year-old woman who underwent chemotherapy, including rituximab and steroid, had reactivation of SARS-CoV-2 68 days after the virus was first detected. She successfully recovered after receiving convalescent plasma and intravenous immunoglobulin. Genomic analysis demonstrated that viruses collected from the nasopharyngeal specimens at day 0 and day 68 had 18 different nucleotide mutations, implying within-host evolution after in-depth epidemiologic investigation.

Indexed as

COVID-19SARS-CoV-2COVID-19 SerotherapyFemaleHumansImmunocompromised HostMiddle AgedRituximabSteroidsRituximabSteroidsCoronavirus Disease 2019ImmunodeficiencySARS-CoV-2Within-Host Evolution

Identifiers

PMID37272563
PMCPMC10244020
OpenAlexW4376454412

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.